Cindy Leissinger, MD
Professor of Medicine, Pediatrics & Pathology
Chief, Section of Hematology & Medical Oncology
Cindy A. Leissinger, MD received her medical degree from Tulane University School of Medicine in New Orleans, Louisiana. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at The National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.
Dr. Leissinger is currently Professor of Medicine, and Clinical Professor of Pediatrics and Pathology at Tulane University. She serves as Chief of the Hematology/Oncology Division. She is also Director of the Louisiana Center for Bleeding and Clotting Disorders. She is a fellow of the American College of Physicians and a member of the American Society of Hematology and the International Society on Thrombosis and Haemostasis. Dr. Leissinger has been a member of the Hemophilia and Thrombosis Research Society since its inception and has served the society in numerous leadership positions.
In addition to caring for patients with coagulation disorders, Dr. Leissinger oversees an active research program that receives funding from the National Institutes of Health as well as numerous other federal and industry sources. She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management. Currently, Dr. Leissinger serves as the principal investigator for two investigator-initiated, multi-institutional clinical trials. The RICH (Rituximab for Inhibitors in Congenital Hemophilia) Study is an open NIH sponsored clinical trial designed to study the effects of rituximab on the eradication of high titer Factor VIII inhibitors. A second clinical trial, the ProFEIBA Study is an international randomized crossover study of FEIBA as secondary prophylaxis for the prevention of bleeds in hemophilia patients with inhibitors. Enrollment and active follow-up for the ProFEIBA study was recently completed and data analysis is ongoing.
Under Dr. Leissinger's direction, Tulane serves as one of 16 member institutions in the NHLBI's Transfusion Medicine/Hemostasis Clinical Trials Network. Several seminal trials developed through this network include platelet transfusion studies, as well as studies of optimal therapy in low incidence hematologic disorders such as ITP and TTP.
Bellissimo D, Christopherson P, Flood V, Gill J, Friedman K, Haberichter S, Abshire T, Lusher J, Hoots K, Shapiro A, Leissinger C, Ragni M and Montgomery R. von Willebrand Factor mutations and new sequence variations identified in healthy controls enrolled in the Zimmerman Program for the Molecular and Clinical Biology of VWD are more frequent in the African American population. Blood, Mar;119:2135-40, 2012. PMID:22197721
Leissinger C, Gringeri A, Antmen B, Berntorp B, Biasoli B, Carpenter C, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu M, Windyga J, Zülfikar B, Mantovani L. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med, Nov;365:1684-92, 2011. PMID:22047559
Leissinger C, Cooper D and Wilke C. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe hemophilia A. Haemophilia, Nov; 17(6):884-889, 2011. PMID:21447095
Kruse-Jarres R, Fang J, Leissinger C and Ganapamo F. Reduced production of IFN-gamma and LT-alpha is associated with successful prednisone therapy in patients with acquired hemophilia A. Thromb Res. Nov;128:86-90, 2011. PMID:21899663
Bonnet P, Gringeri A, Gomperts E, Leissinger C, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, and Berntorp E. Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia A and high-titer inhibitors. American Drug and Health Benefits, July/August;4(4): 2011.
Flood V, Gill J, Morateck P, Christopherson P, Friedman K, Haberichter S, Branchford B, Hoffmann B, Abshire T, Di Paola J, Hoots WK, Leissinger C, Lusher J, Ragni M, Shapiro A, and Montgomery R for the Zimmerman Program for the Molecular and Clinical Biology of VWD. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood, 116(2):280-6, 2010. PMID:20467286
Kruse-Jarres R, Fang J, Leissinger C and Ganapamo F. Rituximab therapy modulates IFN-g and IL-4 gene expression in a patient with acquired hemophilia A. Brit J Haematol, 148:176-8, 2010.
Slichter S, Kaufman R, Assmann S, McCullough J, Triulzi D, Strauss R, Gernsheimer T, Ness P, Brecher M, Josephson C, Konkle B, Woodson R, Ortel T, Hillyer C, Skerrett D, McCrae K, Sloan S, Uhl L, George J, Aquino V, Manno C, McFarland J, Hess J, Leissinger C, Granger S. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med, 362(7):600-613, 2010.
Singleton T, Kruse-Jarres R, Leissinger C. Emergency room care for patients with hemophilia and von Willebrand Disease. J Emergency Medicine 39(2):158-65, 2010.
Morfini M, Laguna P, Leissinger, C. Factor IX pharmacokinetics: Differences between plasma-derived and recombinant products and the clinical and economic implications. Haemophilia,14:873-875, 2008.
Manco-Johnson MJ, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R, Ingeam D, Manco-Johnson ML, Funk S, Jacobson L, Valentino L, Hoots K, Buchanan G, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunga A, Medeiros D, Nugent D, Thomas G, Thompson A, Soucie J, Austin H, Evatt B. Preventing joint disease in young children with severe factor VIII deficiency: results of a prospective, randomized clinical trial. N Engl J Med, 357(6):535-544, 2007.
1430 Tulane Ave, New Orleans, LA 70112 504-988-5228 email@example.com